Answers are grounded in this paper and cite their sources.
This review provides an update on the pathophysiology, diagnosis, and treatment of von Willebrand disease, highlighting the role of recombinant von Willebrand factor.
von Willebrand disease (vWD) is the most common inherited disorder of hemostasis and comprises a spectrum of heterogeneous subtypes. Significant advances have been made in understanding von Willebrand factor ( vWF) gene mutations, resultant physiologic deficits in the vWF peptide, and their correlation to clinical presentation. Diagnostic tests for this disorder are complex, and interpretation requires a thorough understanding of the underlying pathophysiology by the practicing physician. The objective of this review is to summarize our current understanding of pathophysiology, laboratory investigations, and evolving treatment paradigm of vWD with the availability of recombinant von Willebrand factor.
No takes yet. Share an insight, caveat, or question.
Swami et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: